An overview of generalized anxiety disorder: disease state--appropriate therapy (Q33921102)

30 July 2017

1 reference

title

An overview of generalized anxiety disorder: disease state--appropriate therapy (English)

1 reference

generalized anxiety disorder

30 July 2017

main subject

1 reference

Lydiard RB

1

1 reference

30 July 2017

publication date

1 January 2000

1 reference

30 July 2017

published in

Clinical Therapeutics

1 reference

30 July 2017

volume

22 Suppl A

1 reference

30 July 2017

page(s)

A3-19; discussion A20-4

1 reference

Economic costs of anxiety disorders.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

The prevalence of psychiatric disorders in a primary care practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Mental disorders in primary care: epidemiologic, diagnostic, and treatment research directions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Recognition, management, and course of anxiety and depression in general practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Untreated anxiety among adult primary care patients in a Health Maintenance Organization

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

The concept of generalized anxiety disorder: between the too narrow and too wide diagnostic criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Evaluation of the ratings comprising the associated symptom criterion of DSM-III-R generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Cognitions in generalized anxiety disorder and panic disorder patients. A prospective approach.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Somatic presentation of DSM III psychiatric disorders in primary care.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Frustrating patients: physician and patient perspectives among distressed high users of medical services.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Emergence of depressive symptoms in patients receiving alprazolam for panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Paroxetine efficacy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Recent developments in the psychopharmacology of anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Management of SSRI-induced sexual dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Antidepressant-induced sexual dysfunction: review, classification, and suggestions for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Sildenafil citrate for SSRI-induced sexual side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Analysis of individual symptoms in generalized anxiety--a pooled, multistudy, double-blind evaluation of buspirone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

The Clinical Course and Long-Term Management of Generalized Anxiety Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Relapse after Short-Term Drug Therapy in Neurotic Outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

Long-term Treatment of Anxiety and Risk of Withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2989070-0

7 January 2021

10.1016/S0149-2918(00)89070-0

Identifiers

DOI

1 reference

30 July 2017

1 reference